New FDA Standard May Speed Drug Discovery

執筆者
M.L. Baker
M.L. Baker
Published: Jul 23, 2004
Updated: Feb 2, 2021
2 minute read
eWeek のコンテンツおよび製品のおすすめは、編集上の独立性を保っています。パートナーへのリンクをクリックすると、当社が報酬を得る場合があります。 詳細を見る

In an effort that should let FDA experts spend more time analyzing data and less time reformatting it, the FDA on Wednesday announced a new standard that drug sponsors can use to submit data from clinical trials to the agency. The Food and Drug Administration is exploring making the standard a requirement for data submission.

The standard, called Study Data Tabulation Model (STDM), was developed by a nonprofit committee of research companies, the Clinical Data Interchange Standards Consortium. Clinical research organizations, drug sponsors and regulators all will find their data processing efforts “greatly expedited,” said David Handelsman, global strategist for clinical research and development at SAS Inc.

The North Carolina company helps drug sponsors analyze data from clinical trials and is a member of CDISC, along with dozens of other companies, including the largest pharmaceutical firms.

Handelsman said the biggest challenge to creating the standard was companies recognition that they should “differentiate themselves on their science, and not how they process data” and “putting aside their individual and established standards” to create a common one.

/zimages/1/28571.gifClick hereto read about the FDAs push for better predictive technology.

The FDAs acting commissioner applauded the standard and said it could boost efficiency. “The importance of a standard for the exchange of clinical trial data cannot be overstated,” acting commissioner Lester M. Crawford said in a statement.

“FDA reviewers spend far too much valuable time simply reorganizing large amounts of data submitted in varying formats. Having the data presented in a standard structure will improve FDAs ability to evaluate the data and help speed new discoveries to the public,” Crawford said.

The CDISC standard for the exchange of clinical trial laboratory data is approved as a Health Level 7 Reference Information Model (RIM) Version 3 message, making it compatible with standards being developed in the health care community. It also can also be implemented through ASCII, SAS and XML options.

Advertisement

/zimages/1/28571.gifCheck out eWEEK.coms Health Care Center at http://healthcare.eweek.com for the latest news, views and analysis of technologys impact on health care.

M.L. Baker

Monya Baker is co-editor of CIOInsight.com's Health Care Center. She has written for publications including the journal Nature Biotechnology, the Acumen Journal of Sciences and the American Medical Writers Association, among others, and has worked as a consultant with biotechnology companies.

eWeek Logo

eWeek has the latest technology news and analysis, buying guides, and product reviews for IT professionals and technology buyers. The site's focus is on innovative solutions and covering in-depth technical content. eWeek stays on the cutting edge of technology news and IT trends through interviews and expert analysis. Gain insight from top innovators and thought leaders in the fields of IT, business, enterprise software, startups, and more.

TechnologyAdvice が所有・運営しています。 © 2026 TechnologyAdvice. 無断転載を禁じます

広告主に関する開示:このサイトに掲載されている製品の一部は、TechnologyAdvice が報酬を受け取っている企業のものです。この報酬は、製品がこのサイトのどこにどのように表示されるか(表示される順序など)に影響する場合があります。TechnologyAdvice は、市場で入手可能なすべての企業やすべての種類の製品を掲載しているわけではありません。